IJTLD open最新文献_第3页

TB treatment support strategies for children, adolescents, and young adults in a low-incidence setting. 低发病率地区儿童、青少年和青壮年结核病治疗支持策略。

IJTLD open Pub Date : 2025-09-10 eCollection Date: 2025-09-01 DOI: 10.5588/ijtldopen.24.0571

A R Verhage, A C Hesseling, G H Koppelman, H A M Kerstjens, O W Akkerman

{"title":"TB treatment support strategies for children, adolescents, and young adults in a low-incidence setting.","authors":"A R Verhage, A C Hesseling, G H Koppelman, H A M Kerstjens, O W Akkerman","doi":"10.5588/ijtldopen.24.0571","DOIUrl":"10.5588/ijtldopen.24.0571","url":null,"abstract":"Background: Globally, TB programmes should pay attention to the treatment support needs of children and adolescents (0-24 years) given the high disease burden and specific care requirements. We examine how health care workers in a low-incidence setting monitor and support TB treatment and TB preventive treatment (TPT) in this population.Methods: A quantitative web-based cross-sectional survey was conducted from 1 December 2023 to 31 January 2024 among Dutch health care workers routinely caring for persons (0-24 years) in community- and hospital-based TB services.Results: Ninety-three health care workers participated. The most common strategies to monitor TB treatment and TPT were 1) verbal questioning on adherence (100% vs. 99%) and 2) evaluating clinical response to TB treatment (91%). Additional strategies were always used for TB treatment, with a pill organiser being the preferred method, while 50% seldom used extra strategies for TPT. Digital support technologies were rarely used for TB treatment and TPT by 78% and 90% of respondents, respectively.Conclusion: Dutch health care workers relied on traditional methods to support TB treatment adherence with limited use of digital technologies and greater focus on disease than infection. Further research is needed to assess whether these strategies meet young people's needs in TB care and improve outcomes.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 9","pages":"512-518"},"PeriodicalIF":0.0,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12435468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145077093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strengthening the TB response with artificial intelligence and the right to health. 利用人工智能和健康权加强结核病应对工作。

IJTLD open Pub Date : 2025-09-10 eCollection Date: 2025-09-01 DOI: 10.5588/ijtldopen.25.0271

B Citro, S Zaidi, J Malar, O Klymenko, B Hermawan

引用次数: 0

Lung function trajectories in children with pulmonary TB and non-TB lower respiratory tract infections. 肺结核和非结核性下呼吸道感染儿童的肺功能轨迹。

IJTLD open Pub Date : 2025-08-13 eCollection Date: 2025-08-01 DOI: 10.5588/ijtldopen.25.0080

I J Courtney, M Palmer, R Swanepoel, C J Lombard, M van Niekerk, R Dunbar, E D McCollum, H S Schaaf, A Gie, P Goussard, A C Hesseling, V W Jongen, M M van der Zalm

{"title":"Lung function trajectories in children with pulmonary TB and non-TB lower respiratory tract infections.","authors":"I J Courtney, M Palmer, R Swanepoel, C J Lombard, M van Niekerk, R Dunbar, E D McCollum, H S Schaaf, A Gie, P Goussard, A C Hesseling, V W Jongen, M M van der Zalm","doi":"10.5588/ijtldopen.25.0080","DOIUrl":"10.5588/ijtldopen.25.0080","url":null,"abstract":"Background: This longitudinal study compared lung function in children with pulmonary TB (PTB), children with non-TB lower respiratory tract infections (LRTIs) and healthy controls.Methods: Children aged 4-13 years presenting with presumed PTB and their healthy siblings who could perform spirometry were included. Children were classified as having TB, non-TB LRTIs after careful evaluation and during follow-up. Spirometry measurements were completed at baseline and at subsequent study visits during 52 weeks of follow-up. Measurements included forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC using 2022 race-neutral Global Lung Initiative reference ranges.Results: Of 143 children, 46 had TB, 64 had non-TB LRTIs, and 33 were healthy controls. The median age was 6 years (IQR 5-9) and 10 (7%) were living with HIV. Restrictive spirometry patterns were common in both symptomatic groups at the end of follow-up, with a significantly lower FVC in children with TB compared to controls. In multivariable analysis adjusted for time and study group, FEV1 and FVC decreased for both the TB and non-TB LRTI groups, compared to healthy controls.Conclusion: Lung-function trajectories were similar between children with TB and non-TB LRTI, with low FVC one-year after diagnosis.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 8","pages":"471-477"},"PeriodicalIF":0.0,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12352954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144877742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of gene expression in patients prior to TB treatment to identify those associated with pyrazinamide-hepatotoxicity. 分析结核治疗前患者的基因表达，以确定与吡嗪酰胺肝毒性相关的基因表达。

IJTLD open Pub Date : 2025-08-13 eCollection Date: 2025-08-01 DOI: 10.5588/ijtldopen.25.0189

N Zielinski, T T Brehm, N Köhler, P Sánchez Carballo, D Schaub, C Lange, M Reimann

引用次数: 0

Tuberculous endocarditis: a case-based proposal for new diagnostic criteria. 结核性心内膜炎：一个基于病例的新诊断标准建议。

IJTLD open Pub Date : 2025-08-13 eCollection Date: 2025-08-01 DOI: 10.5588/ijtldopen.25.0042

M Higa, H Munakata, T Yamazato, N Abe, N Ohyama, T Fujii, J Nambu, I Nakazato, Y Cho, M Inamine, K Takahashi, H Katano, M Narita

{"title":"Tuberculous endocarditis: a case-based proposal for new diagnostic criteria.","authors":"M Higa, H Munakata, T Yamazato, N Abe, N Ohyama, T Fujii, J Nambu, I Nakazato, Y Cho, M Inamine, K Takahashi, H Katano, M Narita","doi":"10.5588/ijtldopen.25.0042","DOIUrl":"10.5588/ijtldopen.25.0042","url":null,"abstract":"Background: Tuberculous endocarditis (TBE) is a rare but often fatal manifestation of Mycobacterium tuberculosis. Although diagnosis is now possible with advanced techniques, the lack of standardized diagnostic criteria complicates timely recognition and management.Methods: A 79-year-old man with a history of the Bentall procedure for annuloaortic ectasia, presented with fever and chest pain. Imaging revealed infective endocarditis with an aortic root abscess and vegetations. Histopathology identified granulation tissue with multinucleated giant cells, and M. tuberculosis was confirmed via PCR and culture. A literature review of TBE cases was performed to develop systematic diagnostic criteria.Results: The diagnosis of TBE was established through histopathology and molecular methods. Based on this case and prior reports, diagnostic criteria for TBE were developed and categorized as 'Definitive', 'Probable', and 'Possible'. These criteria incorporate clinical, microbiological, histological, and imaging findings to aid in diagnosis. The patient's treatment included surgical intervention combined with antimicrobial therapy, aligning with strategies designed to improve outcomes.Conclusion: This case underscores the importance of considering TBE in infective endocarditis cases, especially those with atypical features. The proposed diagnostic criteria aim to improve the recognition and guide the management of TBE, emphasizing a multidisciplinary approach for better patient outcomes.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 8","pages":"486-492"},"PeriodicalIF":0.0,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12352953/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144877744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Using linezolid as a substitute for the injectable in case of ototoxicity is safer and as effective as all-oral treatment for rifampicin-resistant TB. 在出现耳毒性的情况下，使用利奈唑胺代替注射剂治疗利福平耐药结核病更安全，而且与全口服治疗一样有效。

IJTLD open Pub Date : 2025-08-13 eCollection Date: 2025-08-01 DOI: 10.5588/ijtldopen.25.0151

M B Souleymane, T Decroo, A Soumana, I M Lawan, A-L C Aboubacar, A Gagara-Issoufou, R H Moussa, A-A A Kabirou, I Hamidou, S H Moussa, M Adamou, E Adehossi, S Mamadou, B C de Jong, L Rigouts, A Piubello

{"title":"Using linezolid as a substitute for the injectable in case of ototoxicity is safer and as effective as all-oral treatment for rifampicin-resistant TB.","authors":"M B Souleymane, T Decroo, A Soumana, I M Lawan, A-L C Aboubacar, A Gagara-Issoufou, R H Moussa, A-A A Kabirou, I Hamidou, S H Moussa, M Adamou, E Adehossi, S Mamadou, B C de Jong, L Rigouts, A Piubello","doi":"10.5588/ijtldopen.25.0151","DOIUrl":"10.5588/ijtldopen.25.0151","url":null,"abstract":"Background: WHO recommends all-oral bedaquiline (BDQ) and linezolid (LZD)-containing regimens for rifampicin-resistant TB (RR-TB). In Niger, high cure rates were achieved using an adaptive short treatment regimen (aSTR) with a second-line injectable drug (SLID) and LZD, where LZD replaced the SLID in case of any ototoxicity detected on monthly audiometry. In 2020, WHO recommended a short oral BDQ/LZD regimen (oSTR). However, the success reported for oSTR was lower than for aSTR in Niger. The 'SHOrt ORal Treatment' trial therefore compared the safety and efficacy between aSTR and oSTR in Niger.Methods: In this pragmatic clinical trial, patients with fluoroquinolone-susceptible RR-TB were assigned by alternate months to aSTR or oSTR. Regression models estimated the association between regimen and safety (grade 3-4 adverse events [AEs]) and efficacy (excluding loss to follow-up).Results: Between 2021-2022, 158 RR-TB patients were included, 80 on oSTR and 78 on aSTR. Overall, 34 patients experienced 43 grade 3-4 AEs (anaemia: 15, neurotoxicity: 11, vomiting: 8, hepatitis: 7, arthralgia: 1, QTc prolongation: 1). Grade 3-4 AEs occurred in 26/80 (32.5 %) on oSTR versus 8/78 (10.3%) on aSTR, with anaemia, neurotoxicity and arthralgia being significantly higher in the oSTR group. Ototoxicity and nephrotoxicity appeared more frequently during the aSTR, but none evolved to grade 3. Patients treated with oSTR had a 3-fold increase in grade 3-4 AE (aHR 3.04;95% CI:1.36-6.80). End-of-treatment success was similar for oSTR compared to aSTR.Conclusion: aSTR was safer than oSTR and both approaches had a similar treatment efficacy.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 8","pages":"450-458"},"PeriodicalIF":0.0,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12352956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144877745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acceptability of a clofazimine tablet in children with rifampicin-resistant TB in three high-burden countries. 在三个高负担国家，氯法齐明片剂对患有利福平耐药结核病的儿童的可接受性。

IJTLD open Pub Date : 2025-08-13 eCollection Date: 2025-08-01 DOI: 10.5588/ijtldopen.25.0309

L Viljoen, H R Draper, N T Castillo-Carandang, N Suryavanshi, A Marthinus, A M A Cheong, J D D Ocampo, G Dhumal, S Bagchi, D T Wademan, A Kinikar, M Paradkar, M V G Frias, D J O Casalme, A C Hesseling, A J Garcia-Prats, M Palmer, G Hoddinott

{"title":"Acceptability of a clofazimine tablet in children with rifampicin-resistant TB in three high-burden countries.","authors":"L Viljoen, H R Draper, N T Castillo-Carandang, N Suryavanshi, A Marthinus, A M A Cheong, J D D Ocampo, G Dhumal, S Bagchi, D T Wademan, A Kinikar, M Paradkar, M V G Frias, D J O Casalme, A C Hesseling, A J Garcia-Prats, M Palmer, G Hoddinott","doi":"10.5588/ijtldopen.25.0309","DOIUrl":"10.5588/ijtldopen.25.0309","url":null,"abstract":"Background: Rifampicin-resistant TB (RR-TB) in children is frequently treated with clofazimine (CFZ), widely available as a 100mg gel capsule. This formulation is challenging to administer and is poorly acceptable to children and caregivers. Poor acceptability may negatively impact adherence and treatment outcomes. We describe the acceptability of a novel 50mg CFZ tablet formulation among children in South Africa, India, and the Philippines.Methods: Mixed methods assessments were completed in a moxifloxacin and CFZ safety and pharmacokinetics trial in children with RR-TB. Quantitative data were collected from 36 participants at 4 timepoints. A sub-sample of 26 child/caregiver dyads participated in ∼4 qualitative interviews. Descriptive statistics and thematic analysis were employed.Findings: The median age of n=36 participants (South Africa n=20; India n=6; the Philippines n=10) was 4.9 years. The majority (29/36) received a CFZ gel capsule prior to switching to the tablet formulation. The 50mg tablet had better acceptability scores for taste (p=0.035), smell (p=0.035), and ease of swallowing (p=0.02) compared to gel capsules. Participants described the tablet formulation as easier to administer/take without a lingering smell or taste. Limited concerns were noted on staining.Conclusion: The novel 50mg CFZ tablet has better acceptability and should be prioritised for children wherever possible.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 8","pages":"478-485"},"PeriodicalIF":0.0,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12352948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144877737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Community-based pulmonary rehabilitation for post-TB lung disease - a programmatic intervention. 基于社区的结核病后肺病肺部康复——一种程序化干预措施。

IJTLD open Pub Date : 2025-08-13 eCollection Date: 2025-08-01 DOI: 10.5588/ijtldopen.25.0201

B Stenberg, M Drage, B Matewere, V Alvarez-Manon

{"title":"Community-based pulmonary rehabilitation for post-TB lung disease - a programmatic intervention.","authors":"B Stenberg, M Drage, B Matewere, V Alvarez-Manon","doi":"10.5588/ijtldopen.25.0201","DOIUrl":"10.5588/ijtldopen.25.0201","url":null,"abstract":"Background: Many survivors of pulmonary TB struggle with poor lung health and poor quality of life.Methods: We designed and implemented a culturally appropriate, low-cost, community-based pulmonary rehabilitation (PR) program, and measured its effect on health and wellbeing. We identified former TB patients with pulmonary complaints in 9 districts in Malawi. Those who met the inclusion criteria were divided into groups and given a tailored training program with an educational component and guided through sessions twice per week for 12 weeks. Data on 13 health variables was collected before and after the PR.Results: 467 former TB patients were enrolled. 285 (61%) were female. The mean age was 45 years (16-81). After the 12-week PR, chest pain reduced from 66.4% (310) to 8.8% (41) and cough from 47.5% (222) to 9.6% (45). Moderate and severe dyspnea disappeared, and no one scored below 80 on the Karnofsky Index scale after the PR ended. Endurance and functional capacity measured by 6-minute walk test (6MWT) increased by 15.5%.Conclusion: The 12-week course of PR had a positive effect on people's health and well-being, and it is now integrated into the National TB strategy in Malawi. The benefits of such programs are highly significant for the individual and the broader community. We strongly encourage other countries to implement similar PR programs.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 8","pages":"459-463"},"PeriodicalIF":0.0,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12352951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144877740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Caregiver perspectives on TB-related stigma experienced by young children. 照料者对幼儿结核病相关污名的看法。

IJTLD open Pub Date : 2025-08-13 eCollection Date: 2025-08-01 DOI: 10.5588/ijtldopen.25.0293

L S Johnson, M G Anthony, C Purdy, V Luke, H van Deventer, M van Niekerk, L Viljoen, M M van der Zalm

{"title":"Caregiver perspectives on TB-related stigma experienced by young children.","authors":"L S Johnson, M G Anthony, C Purdy, V Luke, H van Deventer, M van Niekerk, L Viljoen, M M van der Zalm","doi":"10.5588/ijtldopen.25.0293","DOIUrl":"10.5588/ijtldopen.25.0293","url":null,"abstract":"Background: TB-related stigma often stems from a fear of TB infection, power dynamics between social groups, and an association of TB with socially undesirable traits.Methods: This study was conducted in South Africa within a prospective observational TB diagnostic cohort study, 'Umoya.' StopTB stigma questionnaires and activity-based interviews were administered to caregivers of children aged 0-9 years with presumptive pulmonary TB (PTB) 16 to 24 weeks after enrollment.Results: In total, 64 caregivers of 70 children (median age: 2y) with PTB completed the questionnaire. Most children (56%) had a known TB contact in the household. The questionnaire revealed that anticipated stigma was a common concern, with worries about people gossiping or speaking badly about their children (16.7%) or their child's feelings being hurt because of their TB diagnosis (16.7%). Internalized stigma of the child, as perceived by their caregiver, was the least affirmed stigma domain. Overall, caregiver perceptions of internalized stigma did not delay treatment. Twelve of these caregivers were also interviewed, which demonstrated themes of anticipated and internalized stigma, and comparisons to HIV stigma.Conclusion: Deepening our understanding of stigma is critical to improving outcomes and experiences of young children and their families affected by TB.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 8","pages":"443-449"},"PeriodicalIF":0.0,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12352950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144877739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatic safety of pretomanid- and pyrazinamide-containing regimens in TB Alliance clinical trials. 结核病联盟临床试验中含pretomanid和吡嗪酰胺方案的肝脏安全性。

IJTLD open Pub Date : 2025-08-13 eCollection Date: 2025-08-01 DOI: 10.5588/ijtldopen.25.0199

J Nedelman, M Li, M Olugbosi, R Bruning-Barry, J Ambroso, M Cevik, S Gillespie, D J Sloan, M Beumont, E Sun

{"title":"Hepatic safety of pretomanid- and pyrazinamide-containing regimens in TB Alliance clinical trials.","authors":"J Nedelman, M Li, M Olugbosi, R Bruning-Barry, J Ambroso, M Cevik, S Gillespie, D J Sloan, M Beumont, E Sun","doi":"10.5588/ijtldopen.25.0199","DOIUrl":"10.5588/ijtldopen.25.0199","url":null,"abstract":"Background: In STAND and SimpliciTB, clinical trials for drug-susceptible TB, regimens containing pretomanid, pyrazinamide, and other agents (PaZX) had more hepatotoxicity than the standard-of-care regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE). In Nix-TB and ZeNix, clinical trials for drug-resistant TB, the regimen of bedaquiline, pretomanid, and linezolid (BPaL) demonstrated a favorable benefit-risk profile. We compare the hepatic safety of HRZE, PaZX, and BPaL in their respective populations.Methods: In this post-hoc analysis of data from six clinical trials, rates of treatment-emergent elevations of alanine transaminase (ALT) during the first 8 weeks of treatment were estimated by Kaplan-Meier (KM) analysis and compared via log-rank testing and Cox modeling.Results: The KM-estimated probabilities of treatment-emergent ALT elevations greater than 3x the upper limit of normal (>3xULN) were 5.36%, 12.7%, and 11.4% for HRZE, PaZX, and BPaL, respectively. The only significant (p < 0.05) difference was HRZE versus PaZX. The probabilities of ALT elevations >8xULN were 2.68%, 4.58%, and 1.05%, with the only significant difference being PaZX versus BPaL.Conclusions: BPaL and HRZE have similar hepatic safety profiles in their respective populations. Pretomanid and pyrazinamide should be co-administered only when the benefit outweighs the risk.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 8","pages":"464-470"},"PeriodicalIF":0.0,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12352949/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144877741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0